The Clinical and Molecular Characteristics of Community-Associated Staphylococcus aureus Bacteremia in Persons who Inject Drugs at a New York City Tertiary Care Facility During the Opioid Epidemic - Scorecard - MDSpire
Advertisement
The Clinical and Molecular Characteristics of Community-Associated Staphylococcus aureus Bacteremia in Persons who Inject Drugs at a New York City Tertiary Care Facility During the Opioid Epidemic
Clinical Scorecard: Clinical and Molecular Features of Community-Associated Staphylococcus aureus Bacteremia Among Injection Drug Users at a Tertiary Care Center in New York City During the Opioid Crisis
Injection drug use facilitates bloodstream inoculation of S. aureus; molecular diversity of strains without dominant virulence factors; behavioral factors increase infection risk
Target Population
Persons who inject drugs (PWID) with community-associated SAB
Care Setting
Tertiary care medical center, emergency department and inpatient hospital settings
Key Highlights
PWID with SAB are younger, more frequently unstably housed, and have higher rates of infective endocarditis than non-PWID.
S. aureus isolates from PWID are clonally diverse with no dominant strain clusters, possibly due to syringe-exchange programs reducing shared exposures.
No significant associations were found between specific S. aureus virulence factors and clinical complications in PWID.
Guideline-Based Recommendations
Diagnosis
Identify SAB cases with blood cultures positive for S. aureus within 72 hours of ED presentation.
Screen for active injection drug use within the past 12 months to stratify risk.
Evaluate for infective endocarditis in PWID presenting with SAB.
Management
Implement early multidisciplinary intervention targeting PWID with SAB to address infection and substance use.
Consider housing instability and social determinants in care planning for PWID.
Monitoring & Follow-up
Monitor duration of bacteremia and clinical progression closely in PWID due to higher endocarditis risk.
Track methicillin susceptibility to guide antibiotic therapy.
Risks
Higher risk of infective endocarditis among PWID with SAB.
Potential for polymicrobial infections and recurrent SAB episodes in PWID.
Patient & Prescribing Data
Adults ≥18 years with community-associated SAB, including PWID and non-PWID controls
No specific molecular targets identified; treatment guided by clinical diagnosis and methicillin susceptibility; early intervention critical in PWID due to increased endocarditis risk
Clinical Best Practices
Use whole-genome sequencing to understand molecular epidemiology but recognize clinical management relies on standard diagnostic and therapeutic approaches.
Incorporate social and behavioral assessments, including housing status and injection practices, into patient evaluation.
Promote syringe-exchange programs as a harm reduction strategy to potentially reduce shared bacterial exposures.
